Photo by nci from unsplash
With increased neoadjuvant therapy recommendations for early‐stage breast cancer patients due to the COVID‐19 pandemic, it is imperative that molecular diagnostic assays provide reliable results from preoperative core needle biopsies… Click to show full abstract
With increased neoadjuvant therapy recommendations for early‐stage breast cancer patients due to the COVID‐19 pandemic, it is imperative that molecular diagnostic assays provide reliable results from preoperative core needle biopsies (CNB). The study objective was to determine the concordance of MammaPrint and BluePrint results between matched CNB and surgical resection (SR) specimens.
Keywords:
stage breast;
breast cancer;
signature;
core needle;
gene;
early stage
Journal Title: Journal of Surgical Oncology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Surgical Oncology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!